Health TrialsbyHealthPanel

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

ConditionHealthy Aging
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-65
SponsorNutraceuticals Research Institute

About this trial

This study evaluates the subjective effects of injection administration of NR on healthy adult populations.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Provision of signed and dated informed consent form

Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study

Lives within 100 miles of the NRI study site

Any gender, aged 40-65, inclusive

Disqualifiers

Current diagnosis of any seizure disorder, diabetes or insulin resistance, any kidney or liver disorder, heart disease, anemia, cancer, or Parkinson's disease

ANY chronic illness (pre-disease state acceptable)

Out of range phosphate levels at baseline

BMI less than 25 or greater than or equal to 35

Trial design

Design model

Parallel

Treatments tested in this trial

  • Niagen®

    Dietary supplement

    nicotinamide riboside

  • NAD+

    Other intervention

    Nicotinamide adenine dinucleotide

  • Placebo

    Other intervention

    bacteriostatic water

Treatment groups

70 Participants
are divided into 9 treatment groups

9

Treatment groups

See each treatment group below.

Group A: NR via IM injectionExperimental treatment 1 intervention
Group B: NR via subcutaneous injectionExperimental treatment 1 intervention
Group C: NR via IV pushExperimental treatment 1 intervention
Group D: NAD+ via IM injectionActive comparator 1 intervention
Group E: NAD+ via subcutaneous injectionActive comparator 1 intervention
Group F: NAD+ via IV pushActive comparator 1 intervention
Group G: placebo via IM injectionPlacebo comparator 1 intervention
Group H: placebo via subcutaneous injectionPlacebo comparator 1 intervention
Group I: placebo via IV pushPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

McGill Pain Questionnaire

The MPQ contains 78 pain related terms to identify the quantity and type of pain experienced. This multi-dimensional tool has three components; sensory, cognitive, emotional. Higher scores indicate higher levels of pain.

Time frame
1 minute after injection is complete
2

Subjective Discomfort

Subjective discomfort is measured using open-ended questions to qualitatively assess participant comfort during injection.

Time frame
1 minute after injection is complete

Secondary outcomes

1

C-reactive protein

CRP in serum

Time frame
baseline, 90 minutes post injection, day 10
2

Sed Rate

erythrocyte sedimentation rate through whole blood

Time frame
baseline, 90 minutes post injection, day 10
3

plasma viscosity

Plasma viscosity was measured through blood plasma.

Time frame
baseline, 90 minutes post injection, day 10

Other outcomes

1

NRI Sleep Scale

The NRI Sleep scale is a validated scale that measures 6 domains of sleep via a Likert scale. Higher scores indicated greater sleep disturbances.

Time frame
Baseline, Day 10
2

NRI Energy Scale

The NRI Energy scale is a validated scale that measures 6 domains of fatigue via a Likert scale. Higher scores indicated greater fatigue.

Time frame
Baseline, Day 10

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nutraceuticals Research Institute

Lead sponsor

ChromaDex, Inc.

Collaborator

Source ClinicalTrials.gov
Apply now